Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Toward transcriptional therapies for the failing heart: chemical screens to modulate genes
Timothy A. McKinsey, Eric N. Olson
Timothy A. McKinsey, Eric N. Olson
Published March 1, 2005
Citation Information: J Clin Invest. 2005;115(3):538-546. https://doi.org/10.1172/JCI24144.
View: Text | PDF
Review Series

Toward transcriptional therapies for the failing heart: chemical screens to modulate genes

  • Text
  • PDF
Abstract

In response to acute and chronic stresses, the heart frequently undergoes a remodeling process that is accompanied by myocyte hypertrophy, impaired contractility, and pump failure, often culminating in sudden death. The existence of redundant signaling pathways that trigger heart failure poses challenges for therapeutic intervention. Cardiac remodeling is associated with the activation of a pathological gene program that weakens cardiac performance. Thus, targeting the disease process at the level of gene expression represents a potentially powerful therapeutic approach. In this review, we describe strategies for normalizing gene expression in the failing heart with small molecules that control signal transduction pathways directed at transcription factors and associated chromatin-modifying enzymes.

Authors

Timothy A. McKinsey, Eric N. Olson

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Signal-dependent modulation of cardiac genes and hypertrophy by class II...
Signal-dependent modulation of cardiac genes and hypertrophy by class II HDACs. MEF2 recruits class II HDACs to target genes, which results in transcriptional repression due to chromatin condensation. Stimulation of cardiomyocytes with neurohumoral agonists acting through G-protein coupled receptors (GPCRs) activates kinase pathways that culminate with the phosphorylation of class II HDACs and their export to the cytoplasm as a complex with 14-3-3 proteins. The nuclear export protein CRM1 is required for HDAC nuclear export. The release of class II HDACs from MEF2 allows for the association of HATs with MEF2 and consequentially chromatin relaxation and transcriptional activation of fetal cardiac genes.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts